RhumbLine Advisers’s Cytosorbents Corp CTSO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
– Sell
-95
Closed -$6.81K – 4322
2023
Q2
$6.81K Buy
+95
New +$6.01K ﹤0.01% 4023
2022
Q2
– Sell
-2,009
Closed -$128K – 3125
2022
Q1
$128K Sell
2,009
-1
-0% -$72 ﹤0.01% 2844
2021
Q4
$168K Sell
2,010
-33
-2% -$3.7K ﹤0.01% 2871
2021
Q3
$332K Buy
2,043
+22
+1% +$3.58K ﹤0.01% 2726
2021
Q2
$305K Sell
2,021
-107
-5% -$18K ﹤0.01% 2776
2021
Q1
$369K Sell
2,128
-118
-5% -$22.5K ﹤0.01% 2624
2020
Q4
$358K Buy
2,246
+237
+12% +$39.7K ﹤0.01% 2590
2020
Q3
$320K Sell
2,009
-202
-9% -$36.5K ﹤0.01% 2491
2020
Q2
$438K Buy
2,211
+274
+14% +$50.3K ﹤0.01% 2408
2020
Q1
$299K Hold
1,937
– – ﹤0.01% 2410
2019
Q4
$149K Buy
1,937
+11
+0.6% +$960 ﹤0.01% 2815
2019
Q3
$194K Sell
1,926
-15
-0.8% -$1.74K ﹤0.01% 2754
2019
Q2
$257K Sell
1,941
-188
-9% -$25.8K ﹤0.01% 2683
2019
Q1
$322K Buy
2,129
+222
+12% +$34.6K ﹤0.01% 2504
2018
Q4
$308K Buy
1,907
+675
+55% +$134K ﹤0.01% 2532
2018
Q3
$318K Sell
1,232
-62
-5% -$15.5K ﹤0.01% 2488
2018
Q2
$295K Buy
+1,294
New +$245K ﹤0.01% 2541

Other funds holding CTSO

RhumbLine Advisers's CTSO Position: Q3 2023 in Review

RhumbLine Advisers sold out of Cytosorbents Corp (CTSO) in Q3 2023, closing a stake of 95 shares — an estimated $6.81K sold.

RhumbLine Advisers first reported a position in CTSO in Q2 2018 and held it in 17 quarters. The position peaked at $438K in Q2 2020. 51 funds tracked by Wall St. Rank hold CTSO as of Q3 2023.

  • RhumbLine Advisers reported no remaining Cytosorbents Corp position as of Q3 2023 after selling out during the quarter.
  • RhumbLine Advisers sold 95 Cytosorbents Corp shares in Q3 2023, an estimated $6.81K.
  • RhumbLine Advisers first reported a position in Cytosorbents Corp in Q2 2018 and held it in 17 quarters.
  • RhumbLine Advisers's Cytosorbents Corp position peaked at $438K in Q2 2020.
  • 51 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q3 2023.

Based on RhumbLine Advisers's 13F filing for Q3 2023, filed 9 Nov 2023.